Business
Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases
Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company ("Lilly") to develop tolerizing therapies for multiple autoimmune diseases. The collaboration aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression that is c
About this update from Eli Lilly And Company
[{"type":"text","content":"Collaboration unites Repertoire's DECODE™ platform to develop T cell targeted immune medicines with Lilly's commitment to bringing transformative medicines to patients with unmet need","length":191,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., Jan. 29, 2026 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company ("Lilly") to develop tolerizing therapies for multiple autoimmune diseases. The collaboration aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression that is common with currently available therapies.","length":599,"tagName":"p"},{"type":"image","alt":"Repertoire Immune Medicines (PRNewsfoto/Repertoire Immune Medicines)","displaySize":"","headline":null,"caption":"Repertoire Immune Medicines (PRNewsfoto/Repertoire Immune Medicines)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":58,"url":"https://media.zenfs.com/en/prnewswire.com/ad31fe366f1195db080d6a5a5ba9c12f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3XrZe6pWPiBFAzRANBwWLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/ad31fe366f1195db080d6a5a5ba9c12f","width":400,"height":58}},"href":"https://mma.prnewswire.com/media/2397865/Repertoire_tight_logo_BIGTM_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Repertoire will lead collaboration activities until development candidate nomination, and Lilly will lead clinical development, manufacturing, regulatory affairs and commercialization of tolerizing therapies developed under the collaboration. Repertoire will utilize its T cell receptor (TCR)-epitope discovery platform, DECODE™, to discover and develop tolerizing therapy development candidates.","length":401,"tagName":"p"},{"type":"text","content":""This collaboration further expands Repertoire's partnered pipeline of tolerizing therapies and affords us the opportunity to translate the unique discoveries produced by our DECODE platform into potentially paradigm shifting new medicines for autoimmune pa...